TNB-383B is a fully human bispecific T-cell engager (T-BsAb) monoclonal antibody that targets B-cell maturation antigen (BCMA) and CD3, demonstrating potent anti-tumor activity in patients with relapsed or refractory multiple myeloma (MM). It works by binding to BCMA on malignant plasma cells and CD3 on T cells, facilitating T-cell-mediated lysis of myeloma cells while minimizing cytokine release. MW: 123.79 KD.